I-Mab (IMAB) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | U.S.-Listed Chinese Stocks Surge in Overnight Trading Following Politburo's Commitment to Fiscal Support
Moomoo 24/7Sep 26 02:45 ET
US Listed-Chinese Stocks Surge Tuesday on Policy Boost, Who Is Leading the Way
Moomoo NewsSep 25 05:58 ET
Express News | U.S.-Listed Shares of Chinese Firms Jump Premarket After China Announces Stimulus Measures
ReutersSep 24 04:30 ET
I-MAB Appoints New Board Member and Audit Committee
TipRanksSep 23 07:27 ET
H.C. Wainwright Maintains I-Mab(IMAB.US) With Buy Rating, Maintains Target Price $8
Moomoo NewsSep 18 08:31 ET · Ratings
Analysts Are Bullish on These Healthcare Stocks: Clene (CLNN), I-MAB (IMAB)
TipRanksSep 18 08:20 ET · Ratings

Comments

Trytosaveabit

Sep 16 15:07

Update

$I-Mab (IMAB.US)$ Mab Reports Poster Presentation Highlighting Top-line Results From Its Ongoing Phase 1 Clinical Study Of Givastomig AT ESMO 2024
Benzinga· 1 min ago
Expanded Phase 1 monotherapy study of givastomig, a Claudin 18.2 X 4-1BB bispecific antibody immunostimulant, shows promising single-agent activity in heavily pre-treated patients with gastric cancers expressing Claudin 18.2 at low and high levels.The recommended Phase 2 dose for givastomig was determined to be 8-12 mg/kg; giv...

1

Jaguar8

Sep 10 06:55

NEWS

$I-Mab (IMAB.US)$
I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer
- Pharmacokinetic/pharmacodynamic (PK/PD) modeling data from three Phase 1 studies providing dosing support for upcoming clinical trials
- Exposure-Response (E-R) Analysis showed a positive correlation between uliledlimab concentration and ORR probability in mNSCLC patients
- Randomized Phase 2 study of uliledlimab in combination with pembrolizumab plus chemotherapy expected to ...

Moomoo Breakfast US

Sep 12, 2022 07:36

Columns Today's Pre-Market Stock Movers: BMY, ADBE, MSTR, AZN and More

Gapping up
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology (CLVS.US)$ +11.3%, $Cardiff Oncology (CRDF.US)$ +9%, $Immatics (IMTX.US)$ +8.3%, $IDEAYA Biosciences (IDYA.US)$ +8%, $Lyra Therapeutics (LYRA.US)$ +5.7%, $POINT Biopharma (PNT.US)$ +5.7%, $Edgewise Therapeutics (EWTX.US)$ +4.7%, $Concert Pharmaceuticals (CNCE.US)$ +3.6%, $Deciphera Pharmaceuticals (DCPH.US)$ +3.2%, $Veracyte (VCYT.US)$ +2.6%, $SpringWorks Therapeutics (SWTX.US)$ +2.3%,...

10

1

There was once a time when only pharmaceutical stocks could skyrocket to the Moon

this one is going on the watch list
$I-Mab (IMAB.US)$
this pharmaceutical company has tons of potential big money makers in the pipeline. if just one of these Cancer drugs gets approved then it will be a lot of money to be made for this very cheap ticker. they're also anticipating being listed in mainland China and in Hong Kong. this could be a bullish catalyst in the future even without any of the drugs being approv...

+1

2

IMAB I-Mab

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target